CYTK — CYTOKINETICS INC

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1061983 ·
Last close
$51.65
Market Cap
$7.20B
52W High
$88.31
52W Low
$51.38
ADV30
1,951,166
Next earnings
2026-11-04

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 47,557,000 45,341,000 -167,088,000 -190,069,000 1,824,780,000 203,433,000 2,145,951,000
Jun 2026 28,624,000 23,032,000 -179,172,000 -198,762,000 1,924,551,000 255,271,000 2,098,038,000
Mar 2026 19,355,000 16,803,000 -183,618,000 -206,031,000 1,273,478,000 129,843,000 2,100,046,000
Dec 2025 17,755,000 -86,643,000 -178,366,000 -183,031,000 1,424,537,000 122,518,000 2,084,162,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-571,969,000
Investing CF
$-364,767,000
Financing CF
$916,132,000
CapEx
$-16,608,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-6.04
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-4,081,581,000
Inventory
$807,000
Receivables
$33,889,000
ST Investments
$926,588,000
EBIT TTM
$-640,908,000
Pretax Income TTM
$-777,893,000
Interest Exp TTM
$136,985,000
Analysts
18

Yahoo Snapshot (yfinance, live)

Total Revenue
$113,291,000
EBITDA
$-694,489,984
Free Cash Flow
$-397,408,736
Enterprise Value
$7,775,363,072
Total Cash
$1,130,020,992
Total Debt
$1,440,057,984
Shares Out
139,303,351
Trailing EPS
$-6.02
Book Value
$-2.31
ROE
—
ROA
-27.1%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 88,039,000 -612,258,000 -784,955,000 1,424,537,000 2,084,162,000 -659,625,000 -510,009,000
Dec 2024 18,474,000 -536,248,000 -589,526,000 1,401,673,000 1,537,045,000 -135,372,000 -395,890,000
Dec 2023 7,530,000 -496,205,000 -526,244,000 824,316,000 1,210,639,000 -386,323,000 -414,333,000
Dec 2022 94,588,000 -324,202,000 -388,955,000 1,014,775,000 1,122,675,000 -107,900,000 -299,516,000

TTM Snapshot

Revenues TTM
$67,670,000
NetIncome TTM
$-894,002,000
OpCashFlow TTM
—
Assets (Latest)
$1,924,551,000
Forward EPS
$-4.25

Max Pain — expiry 2027-01-15

max pain strike: $40.00 · spot: $51.00 · call oi: 40,768 · put oi: 4,369
Expected Move to 2027-01-15: ±$8.95 (17.55%) — implied range $42.05 – $59.95 · ATM straddle on $50.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
ABVX Abivax S.A. $7.16B $82.10 —
AXSM Axsome Therapeutics, Inc. $7.15B $135.95 —
AMRX Amneal Pharmaceuticals, Inc. $7.36B $21.12 —
ALKS Alkermes plc. $7.64B $45.45 —
CORT CORCEPT THERAPEUTICS INC $7.67B $70.07 —

News headlines (Yahoo Finance, 1h cache)

Cytokinetics Touts MYQORZO Launch Momentum, Plans New FDA Filing
2026-11-17 09:12 · Yahoo
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-11-16 21:00 · Yahoo
Cytokinetics Announces Prescribing Information for MYQORZO® (aficamten) Expanded to Include Data from Phase 3 MAPLE-HCM
2026-11-16 09:00 · Yahoo
Cytokinetics’ MYQORZO Gains Ground as Company Plans Push Into New Heart-Disease Market
2026-11-16 08:12 · Yahoo
Cytokinetics Announces Additional Data Related to Aficamten Presented at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions Held in Collaboration with the American Heart Associ
2026-11-09 12:30 · Yahoo
FDA Decision Watch: Summit’s Lung Cancer Drug, Cytokinetics’ Heart Therapy And Teva’s Igalmi In Spotlight This Week
2026-11-09 10:23 · Yahoo
Cytokinetics' Myqorzo Could Inflect Revenue Starting 2027, RBC Capital Markets Says
2026-11-05 17:18 · Yahoo
Cytokinetics (CYTK) Q3 2026 Earnings Call Transcript
2026-11-05 17:02 · Yahoo
Cytokinetics (CYTK) Could Be 41% Undervalued Following Strong Q3 And Aficamten Data
2026-11-05 10:11 · Yahoo
How MYQORZO Adoption Will Impact Cytokinetics (CYTK) Stock
2026-11-05 06:14 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.